Malin (MLLNF) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Malin Corporation’s investee company, Poseida Therapeutics, is set to be acquired by Roche, leading to a substantial boost in Malin’s equity value and prompting a halt on its previously announced tender offer. The transaction is expected to bring Malin an initial $106.5 million, with further potential earnings, significantly increasing the company’s estimated intrinsic equity value per share. Malin plans to reassess its capital return strategy following this lucrative development.
For further insights into MLLNF stock, check out TipRanks’ Stock Analysis page.